You are here

Investigation of CytoSorb cytokine and myoglobin removal in the treatment of trauma

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-12-C-0038
Agency Tracking Number: A112-105-0585
Amount: $150,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: A11-105
Solicitation Number: 2011.2
Timeline
Solicitation Year: 2011
Award Year: 2012
Award Start Date (Proposal Award Date): 2011-12-08
Award End Date (Contract End Date): 2013-05-24
Small Business Information
7 Deer Park Drive Suite K
Monmouth Junction, NJ -
United States
DUNS: 830014077
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Phillip Chan
 President
 (732) 329-8885
 pchan@cytosorbents.com
Business Contact
 Humayra Ali
Title: Senior Business Analyst
Phone: (732) 329-8885
Email: humayraa@cytosorbents.com
Research Institution
 Stub
Abstract

Polytrauma is the leading cause of military casualties and is a potent trigger of the immune response. Tissue damage, infection, burns, hemorrhage, ischemia and reperfusion, and cell necrosis triggers the immune system to produce excessive levels of cytokines, often called cytokine storm, that can directly kill cells, damage organs, and cause severe inflammation that ultimately leads to multiple organ failure and death in many patients. In severe trauma, crush injury can further cause the breakdown of skeletal muscle, called rhabdomyolysis, and the vast release of myoglobin that can then injure the kidneys and cause renal failure, an independent risk factor for death. Finally, cytokine storm can also disable the immune system, putting patients at high risk of secondary infections. Because of this, multiple organ failure and infection are two of the main causes of late death in trauma patients, yet remains a problem. In this submission, we propose the development of a portable, self-contained, hemoperfusion system that uses our CytoSorb cytokine and myoglobin filter, to prevent or mitigate organ injury in a porcine model of trauma. If successful, this novel therapy could help improve survival of our warfighters and civilians alike, while reducing healthcare costs.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government